SCHEMBL3224883

SCHEMBL3224883

Clc1ccccc1-c1cccn2cncc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 1/20 0.51
QPCTL Q9NXS2 1/20 0.51
IDO1 P14902 3/20 0.45
TDO2 P48775 1/20 0.42
TBXAS1 P24557 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38
P2RX7 Q99572 1/20 0.37
ALDH1A1 P00352 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 2/20 0.37
HSD11B1 P28845 1/20 0.37
HPGD P15428 3/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4855392 0.83 IDO1 (0.47) QPCTQPCTLIDO1TDO2TBXAS1
SCHEMBL12698831 0.79 QPCT (0.59) QPCTQPCTLIDO1TDO2TBXAS1
SCHEMBL3227840 0.79 QPCT (0.51) QPCTQPCTLIDO1TDO2TBXAS1
SCHEMBL3260750 0.79 QPCT (0.67) QPCTQPCTLIDO1TDO2TBXAS1
SCHEMBL3215934 0.78 QPCT (0.66) QPCTQPCTLIDO1TDO2TBXAS1
SCHEMBL12698760 0.76 QPCT (0.68) QPCTQPCTLIDO1TDO2TBXAS1
SCHEMBL3217600 0.76 QPCT (0.62) QPCTQPCTLIDO1TDO2KMT2A
SCHEMBL3227739 0.76 QPCT (0.48) QPCTQPCTLIDO1TDO2KMT2A
SCHEMBL3228833 0.74 QPCT (0.54) QPCTQPCTLIDO1TDO2KMT2A
SCHEMBL12698953 0.72 QPCT (0.55) QPCTQPCTLIDO1TDO2TBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118101-B1 IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2012-09-26 EP claimed
US-7803810-B2 Inhibitors PROBIODRUG AG (DE) 2010-09-28 US claimed
EP-2118101-A1 IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE Probiodrug AG (DE) 2009-11-18 EP claimed
US-20080234313-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2008-09-25 US claimed
WO-2008110523-A1 IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-09-18 WO claimed
EP-2118101-B1 IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2012-09-26 EP disclosed
EP-2118101-B1 IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2012-09-26 EP disclosed
US-7803810-B2 Inhibitors PROBIODRUG AG (DE) 2010-09-28 US disclosed
US-7803810-B2 Inhibitors PROBIODRUG AG (DE) 2010-09-28 US disclosed
US-7803810-B2 Inhibitors PROBIODRUG AG (DE) 2010-09-28 US disclosed
EP-2118101-A1 IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE Probiodrug AG (DE) 2009-11-18 EP disclosed
US-20080234313-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2008-09-25 US disclosed
US-20080234313-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2008-09-25 US disclosed
US-20080234313-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2008-09-25 US disclosed
WO-2008110523-A1 IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-09-18 WO disclosed
WO-2008110523-A1 IMIDAZO [1,5-A] PYRIDINE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234313-A1 NOVEL INHIBITORS SF3A1, HBS1L, SF3A3 QPCT 4475/4885QPCTL 4381/4885IDO1 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.